Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	SUMO ligase activity	RGPD4 RGPD2 RGPD3	2.18e-05	20	55	3	GO:0061665
GeneOntologyMolecularFunction	nuclear estrogen receptor activity	ESR1 ESR2	4.45e-05	4	55	2	GO:0030284
GeneOntologyMolecularFunction	SUMO transferase activity	RGPD4 RGPD2 RGPD3	1.32e-04	36	55	3	GO:0019789
GeneOntologyMolecularFunction	peptidyl-prolyl cis-trans isomerase activity	RGPD4 RGPD2 RGPD3	3.54e-04	50	55	3	GO:0003755
GeneOntologyMolecularFunction	estrogen response element binding	ESR1 ESR2	4.03e-04	11	55	2	GO:0034056
GeneOntologyMolecularFunction	cis-trans isomerase activity	RGPD4 RGPD2 RGPD3	4.20e-04	53	55	3	GO:0016859
GeneOntologyMolecularFunction	RNA polymerase II transcription regulatory region sequence-specific DNA binding	DHX36 ZBTB34 SALL3 ZNF556 ZNF366 ESR1 ESR2 ZNF799 RREB1 ZNF441 DHX9 ZNF563	5.10e-04	1459	55	12	GO:0000977
GeneOntologyMolecularFunction	GTPase activator activity	RGPD4 TBC1D16 RGPD2 RGPD3 TBC1D26	1.01e-03	279	55	5	GO:0005096
GeneOntologyMolecularFunction	double-stranded RNA binding	DHX36 RFTN1 DHX9	1.30e-03	78	55	3	GO:0003725
GeneOntologyMolecularFunction	promoter-specific chromatin binding	ESR1 ESR2 DHX9	1.55e-03	83	55	3	GO:1990841
GeneOntologyMolecularFunction	isomerase activity	RGPD4 RGPD2 CFTR RGPD3	1.93e-03	192	55	4	GO:0016853
GeneOntologyMolecularFunction	nuclear steroid receptor activity	ESR1 ESR2	2.15e-03	25	55	2	GO:0003707
GeneOntologyMolecularFunction	nucleoside-triphosphatase regulator activity	RGPD4 TBC1D16 ARFGEF3 RGPD2 RGPD3 TBC1D26	2.63e-03	507	55	6	GO:0060589
GeneOntologyMolecularFunction	GTPase regulator activity	RGPD4 TBC1D16 ARFGEF3 RGPD2 RGPD3 TBC1D26	2.63e-03	507	55	6	GO:0030695
GeneOntologyBiologicalProcess	positive regulation of glucokinase activity	RGPD4 RGPD2 RGPD3	1.49e-06	9	55	3	GO:0033133
GeneOntologyBiologicalProcess	positive regulation of hexokinase activity	RGPD4 RGPD2 RGPD3	2.12e-06	10	55	3	GO:1903301
GeneOntologyBiologicalProcess	regulation of glucokinase activity	RGPD4 RGPD2 RGPD3	5.03e-06	13	55	3	GO:0033131
GeneOntologyBiologicalProcess	regulation of hexokinase activity	RGPD4 RGPD2 RGPD3	6.40e-06	14	55	3	GO:1903299
GeneOntologyBiologicalProcess	NLS-bearing protein import into nucleus	RGPD4 RGPD2 RGPD3	1.98e-05	20	55	3	GO:0006607
GeneOntologyBiologicalProcess	RNA localization	RGPD4 DHX36 RGPD2 RFTN1 RGPD3 DHX9	2.39e-05	217	55	6	GO:0006403
GeneOntologyBiologicalProcess	RNA transport	RGPD4 RGPD2 RFTN1 RGPD3 DHX9	1.02e-04	175	55	5	GO:0050658
GeneOntologyBiologicalProcess	nucleic acid transport	RGPD4 RGPD2 RFTN1 RGPD3 DHX9	1.02e-04	175	55	5	GO:0050657
GeneOntologyBiologicalProcess	establishment of RNA localization	RGPD4 RGPD2 RFTN1 RGPD3 DHX9	1.11e-04	178	55	5	GO:0051236
GeneOntologyBiologicalProcess	protein peptidyl-prolyl isomerization	RGPD4 RGPD2 RGPD3	1.42e-04	38	55	3	GO:0000413
GeneOntologyBiologicalProcess	G-quadruplex DNA unwinding	DHX36 DHX9	1.45e-04	7	55	2	GO:0044806
GeneOntologyBiologicalProcess	Sertoli cell proliferation	ESR1 ESR2	1.93e-04	8	55	2	GO:0060011
GeneOntologyBiologicalProcess	RNA secondary structure unwinding	DHX36 DHX9	2.48e-04	9	55	2	GO:0010501
GeneOntologyBiologicalProcess	vagina development	ESR1 ESR2	3.78e-04	11	55	2	GO:0060068
GeneOntologyBiologicalProcess	peptidyl-proline modification	RGPD4 RGPD2 RGPD3	4.04e-04	54	55	3	GO:0018208
GeneOntologyBiologicalProcess	response to exogenous dsRNA	DHX36 RFTN1 DHX9	4.27e-04	55	55	3	GO:0043330
GeneOntologyBiologicalProcess	estrogen receptor signaling pathway	ZNF366 ESR1 ESR2	4.74e-04	57	55	3	GO:0030520
GeneOntologyBiologicalProcess	nucleobase-containing compound transport	RGPD4 RGPD2 RFTN1 RGPD3 DHX9	5.24e-04	249	55	5	GO:0015931
GeneOntologyCellularComponent	cytoplasmic periphery of the nuclear pore complex	RGPD4 RGPD2 RGPD3	9.04e-07	8	54	3	GO:1990723
GeneOntologyCellularComponent	nuclear pore cytoplasmic filaments	RGPD4 RGPD2 RGPD3	1.93e-06	10	54	3	GO:0044614
GeneOntologyCellularComponent	annulate lamellae	RGPD4 RGPD2 RGPD3	5.81e-06	14	54	3	GO:0005642
GeneOntologyCellularComponent	nuclear pore nuclear basket	RGPD4 RGPD2 RGPD3	1.29e-05	18	54	3	GO:0044615
GeneOntologyCellularComponent	nuclear inclusion body	RGPD4 RGPD2 RGPD3	1.80e-05	20	54	3	GO:0042405
GeneOntologyCellularComponent	SUMO ligase complex	RGPD4 RGPD2 RGPD3	2.10e-05	21	54	3	GO:0106068
GeneOntologyCellularComponent	inclusion body	RGPD4 RGPD2 RGPD3	1.63e-03	90	54	3	GO:0016234
HumanPheno	Increased circulating gonadotropin level	ESR1 ESR2 CFTR ZFPM2	4.23e-05	91	12	4	HP:0000837
HumanPheno	Abnormality of the anterior pituitary	IARS2 ESR1 ESR2 CFTR BICC1 ZFPM2	8.42e-05	366	12	6	HP:0011747
HumanPheno	Abnormal pituitary gland morphology	IARS2 ESR1 ESR2 CFTR BICC1 ZFPM2	1.19e-04	389	12	6	HP:0012503
HumanPheno	Abnormal circulating gonadotropin concentration	ESR1 ESR2 CFTR ZFPM2	1.61e-04	128	12	4	HP:0030338
MousePheno	elevated level of mitotic sister chromatid exchange	RGPD4 RGPD2 RGPD3	1.48e-05	16	43	3	MP:0003701
MousePheno	spermatic granuloma	ESR1 ADAM7	2.77e-05	3	43	2	MP:0009824
MousePheno	abnormal morula morphology	RGPD4 RGPD2 RGPD3	6.71e-05	26	43	3	MP:0012058
MousePheno	decreased tumor latency	RGPD4 RGPD2 RGPD3	1.04e-04	30	43	3	MP:0010308
MousePheno	failure of blastocyst formation	RGPD4 RGPD2 RGPD3	1.15e-04	31	43	3	MP:0012129
MousePheno	dilated gallbladder	CFTR BICC1	1.38e-04	6	43	2	MP:0009343
MousePheno	abnormal tumor latency	RGPD4 RGPD2 RGPD3	1.52e-04	34	43	3	MP:0010307
MousePheno	abnormal epididymis morphology	RGPD4 RGPD2 ESR1 ADAM7 RGPD3 CXCR2	1.61e-04	269	43	6	MP:0002631
MousePheno	decreased volumetric bone mineral density	ESR1 ESR2	1.92e-04	7	43	2	MP:0013616
MousePheno	abnormal blastocyst formation	RGPD4 RGPD2 RGPD3	2.29e-04	39	43	3	MP:0012128
MousePheno	enlarged epididymis	RGPD4 RGPD2 RGPD3 CXCR2	2.36e-04	99	43	4	MP:0004931
MousePheno	dilated pancreatic duct	CFTR BICC1	2.56e-04	8	43	2	MP:0009144
Domain	GCC2_Rab_bind	RGPD4 RGPD2 RGPD3	9.35e-07	7	57	3	IPR032023
Domain	Rab_bind	RGPD4 RGPD2 RGPD3	9.35e-07	7	57	3	PF16704
Domain	-	RGPD4 RGPD2 RGPD3	3.19e-06	10	57	3	1.10.220.60
Domain	Grip	RGPD4 RGPD2 RGPD3	4.37e-06	11	57	3	SM00755
Domain	GRIP	RGPD4 RGPD2 RGPD3	4.37e-06	11	57	3	PF01465
Domain	Ran_BP1	RGPD4 RGPD2 RGPD3	5.81e-06	12	57	3	PF00638
Domain	GRIP_dom	RGPD4 RGPD2 RGPD3	5.81e-06	12	57	3	IPR000237
Domain	GRIP	RGPD4 RGPD2 RGPD3	5.81e-06	12	57	3	PS50913
Domain	RANBD1	RGPD4 RGPD2 RGPD3	5.81e-06	12	57	3	PS50196
Domain	RanBD	RGPD4 RGPD2 RGPD3	7.54e-06	13	57	3	SM00160
Domain	Ran_bind_dom	RGPD4 RGPD2 RGPD3	7.54e-06	13	57	3	IPR000156
Domain	-	ZBTB34 SALL3 ZNF556 ZNF366 ZBTB47 ZNF799 RREB1 ZNF441 ZFPM2 ZNF563	3.48e-05	679	57	10	3.30.160.60
Domain	zf-C2H2	ZBTB34 SALL3 ZNF556 ZNF366 ZBTB47 ZNF799 RREB1 ZNF441 ZFPM2 ZNF563	4.13e-05	693	57	10	PF00096
Domain	Znf_C2H2/integrase_DNA-bd	ZBTB34 SALL3 ZNF556 ZNF366 ZBTB47 ZNF799 RREB1 ZNF441 ZFPM2 ZNF563	4.18e-05	694	57	10	IPR013087
Domain	Oest_rcpt/oest-rel_rcp	ESR1 ESR2	9.10e-05	5	57	2	IPR024178
Domain	ZINC_FINGER_C2H2_2	ZBTB34 SALL3 ZNF556 ZNF366 ZBTB47 ZNF799 RREB1 ZNF441 ZFPM2 ZNF563	1.05e-04	775	57	10	PS50157
Domain	ZINC_FINGER_C2H2_1	ZBTB34 SALL3 ZNF556 ZNF366 ZBTB47 ZNF799 RREB1 ZNF441 ZFPM2 ZNF563	1.07e-04	777	57	10	PS00028
Domain	Znf_C2H2-like	ZBTB34 SALL3 ZNF556 ZNF366 ZBTB47 ZNF799 RREB1 ZNF441 ZFPM2 ZNF563	1.31e-04	796	57	10	IPR015880
Domain	Znf_C2H2	ZBTB34 SALL3 ZNF556 ZNF366 ZBTB47 ZNF799 RREB1 ZNF441 ZFPM2 ZNF563	1.44e-04	805	57	10	IPR007087
Domain	TPR_REGION	RGPD4 RGPD2 RGPD3 DNAH2 TTC13	1.46e-04	165	57	5	PS50293
Domain	TPR	RGPD4 RGPD2 RGPD3 DNAH2 TTC13	1.46e-04	165	57	5	PS50005
Domain	ZnF_C2H2	ZBTB34 SALL3 ZNF556 ZNF366 ZBTB47 ZNF799 RREB1 ZNF441 ZFPM2 ZNF563	1.48e-04	808	57	10	SM00355
Domain	RabGAP-TBC	TBC1D16 TBC1D28 TBC1D26	5.67e-04	53	57	3	PF00566
Domain	TBC_RABGAP	TBC1D16 TBC1D28 TBC1D26	6.32e-04	55	57	3	PS50086
Domain	Rab-GTPase-TBC_dom	TBC1D16 TBC1D28 TBC1D26	6.32e-04	55	57	3	IPR000195
Domain	TPR	RGPD4 RGPD2 RGPD3 TTC13	6.46e-04	129	57	4	SM00028
Domain	TPR_repeat	RGPD4 RGPD2 RGPD3 TTC13	7.25e-04	133	57	4	IPR019734
Domain	TPR-contain_dom	RGPD4 RGPD2 RGPD3 TTC13	1.13e-03	150	57	4	IPR013026
Domain	DUF1605	DHX36 DHX9	1.21e-03	17	57	2	IPR011709
Domain	OB_NTP_bind	DHX36 DHX9	1.21e-03	17	57	2	PF07717
Domain	HA2	DHX36 DHX9	1.36e-03	18	57	2	SM00847
Domain	HA2	DHX36 DHX9	1.36e-03	18	57	2	PF04408
Domain	Helicase-assoc_dom	DHX36 DHX9	1.36e-03	18	57	2	IPR007502
Domain	BRCT	DBF4 REV1	1.51e-03	19	57	2	PF00533
Domain	BRCT	DBF4 REV1	2.03e-03	22	57	2	SM00292
Domain	-	DBF4 REV1	2.22e-03	23	57	2	3.40.50.10190
Domain	zf-C2H2_6	ZNF556 ZNF366 ZBTB47 ZNF799 RREB1	2.67e-03	314	57	5	PF13912
Domain	BRCT	DBF4 REV1	2.84e-03	26	57	2	PS50172
Domain	BRCT_dom	DBF4 REV1	3.29e-03	28	57	2	IPR001357
Domain	-	RGPD4 RGPD2 RGPD3 TTC13	3.66e-03	207	57	4	1.25.40.10
Domain	DNA/RNA_helicase_DEAH_CS	DHX36 DHX9	5.10e-03	35	57	2	IPR002464
Domain	TPR-like_helical_dom	RGPD4 RGPD2 RGPD3 TTC13	5.56e-03	233	57	4	IPR011990
Domain	DEAH_ATP_HELICASE	DHX36 DHX9	6.00e-03	38	57	2	PS00690
Domain	LAM_G_DOMAIN	NRXN2 CNTNAP4	6.00e-03	38	57	2	PS50025
Domain	Laminin_G_2	NRXN2 CNTNAP4	6.63e-03	40	57	2	PF02210
Domain	EGF	STAB2 NRXN2 CNTNAP4	6.73e-03	126	57	3	PF00008
Domain	LamG	NRXN2 CNTNAP4	7.97e-03	44	57	2	SM00282
Domain	EGF-like_CS	STAB2 NRXN2 CNTNAP4 EPHA7	8.24e-03	261	57	4	IPR013032
Domain	EGF_2	STAB2 NRXN2 CNTNAP4 EPHA7	8.69e-03	265	57	4	PS01186
Domain	zf-C4	ESR1 ESR2	8.69e-03	46	57	2	PF00105
Domain	Znf_hrmn_rcpt	ESR1 ESR2	8.69e-03	46	57	2	IPR001628
Domain	Nuclear_hrmn_rcpt	ESR1 ESR2	8.69e-03	46	57	2	IPR001723
Domain	NUCLEAR_REC_DBD_2	ESR1 ESR2	8.69e-03	46	57	2	PS51030
Domain	NUCLEAR_REC_DBD_1	ESR1 ESR2	8.69e-03	46	57	2	PS00031
Domain	ZnF_C4	ESR1 ESR2	8.69e-03	46	57	2	SM00399
Domain	-	ESR1 ESR2	9.06e-03	47	57	2	1.10.565.10
Pathway	BIOCARTA_RANBP2_PATHWAY	RGPD4 RGPD2 RGPD3	1.68e-05	18	40	3	MM1549
Pathway	REACTOME_DEX_H_BOX_HELICASES_ACTIVATE_TYPE_I_IFN_AND_INFLAMMATORY_CYTOKINES_PRODUCTION	DHX36 DHX9	1.63e-04	7	40	2	MM14930
Pathway	REACTOME_DEX_H_BOX_HELICASES_ACTIVATE_TYPE_I_IFN_AND_INFLAMMATORY_CYTOKINES_PRODUCTION	DHX36 DHX9	1.63e-04	7	40	2	M27227
Pathway	KEGG_MEDICUS_ENV_FACTOR_E2_TO_NUCLEAR_INITIATED_ESTROGEN_SIGNALING_PATHWAY	ESR1 ESR2	1.63e-04	7	40	2	M47805
Pathway	REACTOME_NUCLEAR_PORE_COMPLEX_NPC_DISASSEMBLY	RGPD4 RGPD2 RGPD3	1.94e-04	40	40	3	MM14945
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_SMALL_RNAS	RGPD4 RGPD2 RGPD3	2.09e-04	41	40	3	MM15200
Pathway	REACTOME_SUMOYLATION_OF_SUMOYLATION_PROTEINS	RGPD4 RGPD2 RGPD3	2.25e-04	42	40	3	MM15039
Pathway	REACTOME_TRANSPORT_OF_THE_SLBP_DEPENDANT_MATURE_MRNA	RGPD4 RGPD2 RGPD3	2.41e-04	43	40	3	MM14609
Pathway	REACTOME_SUMOYLATION_OF_UBIQUITINYLATION_PROTEINS	RGPD4 RGPD2 RGPD3	3.15e-04	47	40	3	MM14939
Pathway	REACTOME_GENE_SILENCING_BY_RNA	RGPD4 RGPD2 RGPD3	3.56e-04	49	40	3	MM14837
Pathway	REACTOME_TRANSPORT_OF_MATURE_MRNAS_DERIVED_FROM_INTRONLESS_TRANSCRIPTS	RGPD4 RGPD2 RGPD3	3.78e-04	50	40	3	MM14610
Pathway	REACTOME_SUMOYLATION_OF_DNA_REPLICATION_PROTEINS	RGPD4 RGPD2 RGPD3	4.01e-04	51	40	3	MM15151
Pathway	KEGG_MEDICUS_REFERENCE_NUCLEAR_INITIATED_ESTROGEN_SIGNALING_PATHWAY	ESR1 ESR2	4.25e-04	11	40	2	M47503
Pathway	REACTOME_NUCLEAR_ENVELOPE_BREAKDOWN	RGPD4 RGPD2 RGPD3	5.01e-04	55	40	3	MM14917
Pathway	KEGG_MEDICUS_ENV_FACTOR_NNK_NNN_TO_PI3K_SIGNALING_PATHWAY_N01350	ESR1 ESR2	5.09e-04	12	40	2	M47798
Pathway	REACTOME_SUMOYLATION_OF_RNA_BINDING_PROTEINS	RGPD4 RGPD2 RGPD3	5.86e-04	58	40	3	MM15149
Pathway	REACTOME_SNRNP_ASSEMBLY	RGPD4 RGPD2 RGPD3	5.86e-04	58	40	3	MM14736
Pathway	WP_SULFATASE_AND_AROMATASE_PATHWAY	ESR1 ESR2	6.99e-04	14	40	2	M48085
Pathway	REACTOME_SUMOYLATION_OF_CHROMATIN_ORGANIZATION_PROTEINS	RGPD4 RGPD2 RGPD3	8.18e-04	65	40	3	MM15147
Pathway	KEGG_MEDICUS_ENV_FACTOR_E2_TO_RAS_ERK_SIGNALING_PATHWAY	ESR1 ESR2	9.19e-04	16	40	2	M47801
Pathway	REACTOME_CELL_CYCLE_CHECKPOINTS	RGPD4 RGPD2 DBF4 RGPD3 PSMD2	9.60e-04	271	40	5	MM15388
Pathway	REACTOME_REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE	RGPD4 RGPD2 RGPD3	1.15e-03	73	40	3	MM14948
Pathway	REACTOME_SUMOYLATION	RGPD4 RGPD2 ESR1 RGPD3	1.30e-03	169	40	4	MM14919
Pathway	REACTOME_GLUCOSE_METABOLISM	RGPD4 RGPD2 RGPD3	1.60e-03	82	40	3	MM15394
Pathway	REACTOME_SUMOYLATION_OF_DNA_DAMAGE_RESPONSE_AND_REPAIR_PROTEINS	RGPD4 RGPD2 RGPD3	1.72e-03	84	40	3	MM14929
Pathway	REACTOME_TRANSPORT_OF_MATURE_TRANSCRIPT_TO_CYTOPLASM	RGPD4 RGPD2 RGPD3	1.84e-03	86	40	3	MM15413
Pathway	KEGG_MEDICUS_REFERENCE_E2_ER_RAS_ERK_SIGNALING_PATHWAY	ESR1 ESR2	1.91e-03	23	40	2	M47799
Pathway	REACTOME_SEPARATION_OF_SISTER_CHROMATIDS	RGPD4 RGPD2 RGPD3 PSMD2	2.12e-03	193	40	4	MM14890
Pubmed	Interconversion of red opsin isoforms by the cyclophilin-related chaperone protein Ran-binding protein 2.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	9037092
Pubmed	Complex genomic rearrangements lead to novel primate gene function.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	15710750
Pubmed	Genomic organization, expression, and localization of murine Ran-binding protein 2 (RanBP2) gene.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	11353387
Pubmed	Microglial activation in an amyotrophic lateral sclerosis-like model caused by Ranbp2 loss and nucleocytoplasmic transport impairment in retinal ganglion neurons.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	30944974
Pubmed	Nucleoporin Nup358 drives the differentiation of myeloid-biased multipotent progenitors by modulating HDAC3 nuclear translocation.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	38838144
Pubmed	Retina-specifically expressed novel subtypes of bovine cyclophilin.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	7559465
Pubmed	Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	17372272
Pubmed	Proteostatic Remodeling of Small Heat Shock Chaperones─Crystallins by Ran-Binding Protein 2─and the Peptidyl-Prolyl cis-trans Isomerase and Chaperone Activities of Its Cyclophilin Domain.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	38657106
Pubmed	Nup358, a nucleoporin, functions as a key determinant of the nuclear pore complex structure remodeling during skeletal myogenesis.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	21205196
Pubmed	Haploinsufficiency of RanBP2 is neuroprotective against light-elicited and age-dependent degeneration of photoreceptor neurons.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	18949001
Pubmed	Selective impairment of a subset of Ran-GTP-binding domains of ran-binding protein 2 (Ranbp2) suffices to recapitulate the degeneration of the retinal pigment epithelium (RPE) triggered by Ranbp2 ablation.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	25187515
Pubmed	Localization of the Ran-GTP binding protein RanBP2 at the cytoplasmic side of the nuclear pore complex.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	8603673
Pubmed	Uncoupling phototoxicity-elicited neural dysmorphology and death by insidious function and selective impairment of Ran-binding protein 2 (Ranbp2).	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	26632511
Pubmed	Differential loss of prolyl isomerase or chaperone activity of Ran-binding protein 2 (Ranbp2) unveils distinct physiological roles of its cyclophilin domain in proteostasis.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	24403063
Pubmed	Distinct and atypical intrinsic and extrinsic cell death pathways between photoreceptor cell types upon specific ablation of Ranbp2 in cone photoreceptors.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	23818861
Pubmed	Kinesin-1 and mitochondrial motility control by discrimination of structurally equivalent but distinct subdomains in Ran-GTP-binding domains of Ran-binding protein 2.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	23536549
Pubmed	Identification of RanBP2- and kinesin-mediated transport pathways with restricted neuronal and subcellular localization.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	12191015
Pubmed	Ranbp2 haploinsufficiency mediates distinct cellular and biochemical phenotypes in brain and retinal dopaminergic and glia cells elicited by the Parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	22821000
Pubmed	Neuroprotection resulting from insufficiency of RANBP2 is associated with the modulation of protein and lipid homeostasis of functionally diverse but linked pathways in response to oxidative stress.	RGPD4 RGPD2 RGPD3	1.45e-07	7	57	3	20682751
Pubmed	A direct physical interaction between Nanog and Sox2 regulates embryonic stem cell self-renewal.	RGPD4 RGPD2 ZBTB34 SALL3 RGPD3 DHX9	1.50e-07	146	57	6	23892456
Pubmed	The nucleoporin RanBP2 tethers the cAMP effector Epac1 and inhibits its catalytic activity.	RGPD4 RGPD2 RGPD3	2.32e-07	8	57	3	21670213
Pubmed	Critical role of RanBP2-mediated SUMOylation of Small Heterodimer Partner in maintaining bile acid homeostasis.	RGPD4 RGPD2 RGPD3	2.32e-07	8	57	3	27412403
Pubmed	Mice lacking Ran binding protein 1 are viable and show male infertility.	RGPD4 RGPD2 RGPD3	2.32e-07	8	57	3	21310149
Pubmed	The distribution of phosphorylated SR proteins and alternative splicing are regulated by RANBP2.	RGPD4 RGPD2 RGPD3	2.32e-07	8	57	3	22262462
Pubmed	Zap70 and downstream RanBP2 are required for the exact timing of the meiotic cell cycle in oocytes.	RGPD4 RGPD2 RGPD3	2.32e-07	8	57	3	28745977
Pubmed	Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha.	RGPD4 RGPD2 RGPD3	3.48e-07	9	57	3	18394993
Pubmed	Loss of Ranbp2 in motoneurons causes disruption of nucleocytoplasmic and chemokine signaling, proteostasis of hnRNPH3 and Mmp28, and development of amyotrophic lateral sclerosis-like syndromes.	RGPD4 RGPD2 RGPD3	3.48e-07	9	57	3	28100513
Pubmed	Association of the kinesin-binding domain of RanBP2 to KIF5B and KIF5C determines mitochondria localization and function.	RGPD4 RGPD2 RGPD3	3.48e-07	9	57	3	17887960
Pubmed	The docking of kinesins, KIF5B and KIF5C, to Ran-binding protein 2 (RanBP2) is mediated via a novel RanBP2 domain.	RGPD4 RGPD2 RGPD3	3.48e-07	9	57	3	11553612
Pubmed	The zinc finger cluster domain of RanBP2 is a specific docking site for the nuclear export factor, exportin-1.	RGPD4 RGPD2 RGPD3	3.48e-07	9	57	3	10601307
Pubmed	The cyclophilin-like domain mediates the association of Ran-binding protein 2 with subunits of the 19 S regulatory complex of the proteasome.	RGPD4 RGPD2 RGPD3	3.48e-07	9	57	3	9733766
Pubmed	Impairments in age-dependent ubiquitin proteostasis and structural integrity of selective neurons by uncoupling Ran GTPase from the Ran-binding domain 3 of Ranbp2 and identification of novel mitochondrial isoforms of ubiquitin-conjugating enzyme E2I (ubc9) and Ranbp2.	RGPD4 RGPD2 RGPD3	3.48e-07	9	57	3	28877029
Pubmed	The RanBP2/RanGAP1*SUMO1/Ubc9 SUMO E3 ligase is a disassembly machine for Crm1-dependent nuclear export complexes.	RGPD4 RGPD2 RGPD3	4.97e-07	10	57	3	27160050
Pubmed	Parkin ubiquitinates and promotes the degradation of RanBP2.	RGPD4 RGPD2 RGPD3	4.97e-07	10	57	3	16332688
Pubmed	Cyclophilin-related protein RanBP2 acts as chaperone for red/green opsin.	RGPD4 RGPD2 RGPD3	4.97e-07	10	57	3	8857542
Pubmed	Ran-dependent docking of importin-beta to RanBP2/Nup358 filaments is essential for protein import and cell viability.	RGPD4 RGPD2 RGPD3	4.97e-07	10	57	3	21859863
Pubmed	RanBP2 modulates Cox11 and hexokinase I activities and haploinsufficiency of RanBP2 causes deficits in glucose metabolism.	RGPD4 RGPD2 RGPD3	6.82e-07	11	57	3	17069463
Pubmed	An Rtn4/Nogo-A-interacting micropeptide modulates synaptic plasticity with age.	RGPD4 RGPD2 RGPD3	6.82e-07	11	57	3	35771867
Pubmed	T-cell receptor (TCR) signaling promotes the assembly of RanBP2/RanGAP1-SUMO1/Ubc9 nuclear pore subcomplex via PKC-θ-mediated phosphorylation of RanGAP1.	RGPD4 RGPD2 RGPD3	6.82e-07	11	57	3	34110283
Pubmed	Ankyrin-G induces nucleoporin Nup358 to associate with the axon initial segment of neurons.	RGPD4 RGPD2 RGPD3	1.18e-06	13	57	3	31427429
Pubmed	Limited expression of nuclear pore membrane glycoprotein 210 in cell lines and tissues suggests cell-type specific nuclear pores in metazoans.	RGPD4 RGPD2 RGPD3	1.87e-06	15	57	3	14697343
Pubmed	Reduced expression of oestrogen receptor-β is associated with tumour invasion and metastasis in oestrogen receptor-α-negative human papillary thyroid carcinoma.	ESR1 ESR2	2.64e-06	2	57	2	29655286
Pubmed	CpG methylation of the ERalpha and ERbeta genes in breast cancer.	ESR1 ESR2	2.64e-06	2	57	2	15254780
Pubmed	Chronic estradiol treatment reduces platelet responses and protects mice from thromboembolism through the hematopoietic estrogen receptor α.	ESR1 ESR2	2.64e-06	2	57	2	22776819
Pubmed	Alleles and haplotypes of the estrogen receptor alpha gene are associated with an increased risk of spontaneous abortion.	ESR1 ESR2	2.64e-06	2	57	2	19200973
Pubmed	Estrogen receptor alpha and beta polymorphisms are associated with semen quality.	ESR1 ESR2	2.64e-06	2	57	2	19959825
Pubmed	Role of estrogen receptor α and β in preserving hippocampal function during aging.	ESR1 ESR2	2.64e-06	2	57	2	23392694
Pubmed	Effects of ERβ and ERα on OVX-induced changes in adiposity and insulin resistance.	ESR1 ESR2	2.64e-06	2	57	2	32053493
Pubmed	Different expression of estrogen receptors alpha and beta in human myometrium and leiomyoma during the proliferative phase of the menstrual cycle and after GnRHa treatment.	ESR1 ESR2	2.64e-06	2	57	2	11826769
Pubmed	Ablation of estrogen receptor alpha or beta eliminates sex differences in mechanical pain threshold in normal and inflamed mice.	ESR1 ESR2	2.64e-06	2	57	2	19285805
Pubmed	Expression of estrogen receptors in the pelvic floor of pre- and post-menopausal women presenting pelvic organ prolapse.	ESR1 ESR2	2.64e-06	2	57	2	22038234
Pubmed	Differential association of juvenile and adult systemic lupus erythematosus with genetic variants of oestrogen receptors alpha and beta.	ESR1 ESR2	2.64e-06	2	57	2	20961965
Pubmed	Polymorphisms in the estrogen receptor beta gene but not estrogen receptor alpha gene affect the risk of developing endometriosis in a Japanese population.	ESR1 ESR2	2.64e-06	2	57	2	15193490
Pubmed	Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo.	ESR1 ESR2	2.64e-06	2	57	2	33159119
Pubmed	Phytoestrogens induce differential estrogen receptor alpha- or Beta-mediated responses in transfected breast cancer cells.	ESR1 ESR2	2.64e-06	2	57	2	16118406
Pubmed	Expression of aromatase and estrogen receptors in lumbar motoneurons of mice.	ESR1 ESR2	2.64e-06	2	57	2	28501695
Pubmed	Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta.	ESR1 ESR2	2.64e-06	2	57	2	20372779
Pubmed	Human permanent tooth sizes are associated with genes encoding oestrogen receptors.	ESR1 ESR2	2.64e-06	2	57	2	32985343
Pubmed	The distribution of cells containing estrogen receptor-alpha (ERalpha) and ERbeta messenger ribonucleic acid in the preoptic area and hypothalamus of the sheep: comparison of males and females.	ESR1 ESR2	2.64e-06	2	57	2	10919284
Pubmed	Estrogen Receptor Expression in Pancreatic Adenocarcinoma: Time to Reconsider Evidence.	ESR1 ESR2	2.64e-06	2	57	2	34860807
Pubmed	Receptor null mice reveal contrasting roles for estrogen receptor alpha and beta in reproductive tissues.	ESR1 ESR2	2.64e-06	2	57	2	11162937
Pubmed	Estrogen receptor alpha and beta polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy?	ESR1 ESR2	2.64e-06	2	57	2	16735942
Pubmed	Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours.	ESR1 ESR2	2.64e-06	2	57	2	16880783
Pubmed	Endogenous estradiol and its association with estrogen receptor gene polymorphisms.	ESR1 ESR2	2.64e-06	2	57	2	16949384
Pubmed	Estrogen receptor genotype and risk of cognitive impairment in elders: findings from the Health ABC study.	ESR1 ESR2	2.64e-06	2	57	2	17889406
Pubmed	Sex steroid hormone polymorphisms, high-density lipoprotein cholesterol, and apolipoprotein A-1 from the Study of Women's Health Across the Nation (SWAN).	ESR1 ESR2	2.64e-06	2	57	2	16949390
Pubmed	The association of bone mineral density with estrogen receptor gene polymorphisms.	ESR1 ESR2	2.64e-06	2	57	2	16949392
Pubmed	Sex differences in exercise-induced physiological myocardial hypertrophy are modulated by oestrogen receptor beta.	ESR1 ESR2	2.64e-06	2	57	2	24654233
Pubmed	Sex-Specific Involvement of Estrogen Receptors in Behavioral Responses to Stress and Psychomotor Activation.	ESR1 ESR2	2.64e-06	2	57	2	30863326
Pubmed	Estrogen receptor α- (ERα), but not ERβ-signaling, is crucially involved in mechanostimulation of bone fracture healing by whole-body vibration.	ESR1 ESR2	2.64e-06	2	57	2	29367057
Pubmed	Immunohistochemical expression of estrogen receptors alpha and beta in lobular neoplasia.	ESR1 ESR2	2.64e-06	2	57	2	17924141
Pubmed	Differential expression of estrogen receptor α and β isoforms in multiple and solitary leiomyomas.	ESR1 ESR2	2.64e-06	2	57	2	26529545
Pubmed	Roles of estrogen receptor α and β in the regulation of proliferation in endometrial carcinoma.	ESR1 ESR2	2.64e-06	2	57	2	32853964
Pubmed	Localization of estrogen and androgen receptors in male reproductive tissues of mice and rats.	ESR1 ESR2	2.64e-06	2	57	2	15278948
Pubmed	Pregnancy and oestrogen regulate sinoatrial node calcium homeostasis and accelerate pacemaking.	ESR1 ESR2	2.64e-06	2	57	2	29800268
Pubmed	The differential fate of mesonephric tubular-derived efferent ductules in estrogen receptor-alpha knockout versus wild-type female mice.	ESR1 ESR2	2.64e-06	2	57	2	11014235
Pubmed	17Beta-estradiol regulation of the mRNA expression of T-type calcium channel subunits: role of estrogen receptor alpha and estrogen receptor beta.	ESR1 ESR2	2.64e-06	2	57	2	19003958
Pubmed	Differential expression patterns and clinical significance of estrogen receptor-α and β in papillary thyroid carcinoma.	ESR1 ESR2	2.64e-06	2	57	2	24884830
Pubmed	Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERalpha/ERbeta ratio.	ESR1 ESR2	2.64e-06	2	57	2	18955141
Pubmed	Estrogen receptor-beta mediates male-female differences in the development of pressure overload hypertrophy.	ESR1 ESR2	2.64e-06	2	57	2	15374829
Pubmed	Bioassays for estrogenic activity: development and validation of estrogen receptor (ERalpha/ERbeta) and breast cancer proliferation bioassays to measure serum estrogenic activity in clinical studies.	ESR1 ESR2	2.64e-06	2	57	2	19382890
Pubmed	Variants in estrogen receptor alpha gene are associated with phenotypical expression of obsessive-compulsive disorder.	ESR1 ESR2	2.64e-06	2	57	2	20850223
Pubmed	The influence of ESR1 rs9340799 and ESR2 rs1256049 polymorphisms on prostate cancer risk.	ESR1 ESR2	2.64e-06	2	57	2	24859835
Pubmed	Support of a bi-faceted role of estrogen receptor β (ERβ) in ERα-positive breast cancer cells.	ESR1 ESR2	2.64e-06	2	57	2	24192230
Pubmed	Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice.	ESR1 ESR2	2.64e-06	2	57	2	11557741
Pubmed	Transgenic models of metabolic bone disease: impact of estrogen receptor deficiency on skeletal metabolism.	ESR1 ESR2	2.64e-06	2	57	2	12952206
Pubmed	Determination of the isoflavone composition and estrogenic activity of commercial dietary supplements based on soy or red clover.	ESR1 ESR2	2.64e-06	2	57	2	26023053
Pubmed	Both estrogen receptor-alpha and -beta are required for sexual differentiation of the anteroventral periventricular area in mice.	ESR1 ESR2	2.64e-06	2	57	2	16239299
Pubmed	Estrogen receptor beta-deficient female mice develop a bladder phenotype resembling human interstitial cystitis.	ESR1 ESR2	2.64e-06	2	57	2	17522255
Pubmed	Ratio of Circulating Estrogen Receptors Beta and Alpha (ERβ/ERα) Indicates Endoscopic Activity in Patients with Crohn's Disease.	ESR1 ESR2	2.64e-06	2	57	2	28823012
Pubmed	Estrogen receptor polymorphisms and the vascular effects of hormone therapy.	ESR1 ESR2	2.64e-06	2	57	2	21106950
Pubmed	Untangling the human estrogen receptor gene structure.	ESR1 ESR2	2.64e-06	2	57	2	12111450
Pubmed	Generation and reproductive phenotypes of mice lacking estrogen receptor beta.	ESR1 ESR2	2.64e-06	2	57	2	9861029
Pubmed	Molecular analysis of the estrogen receptor alpha gene in men with coronary artery disease: association with disease status.	ESR1 ESR2	2.64e-06	2	57	2	12691862
Pubmed	Association of promoter methylation of ERα and ERβ with sporadic breast cancer--a study from North India.	ESR1 ESR2	2.64e-06	2	57	2	24833090
Pubmed	Long-Term Neonatal Estrogen Exposure Causes Irreversible Inhibition of LH Pulses by Suppressing Arcuate Kisspeptin Expression via Estrogen Receptors α and β in Female Rodents.	ESR1 ESR2	2.64e-06	2	57	2	28368450
Pubmed	Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury.	ESR1 ESR2	2.64e-06	2	57	2	15698835
Pubmed	The oxidative stress in breast tumors of postmenopausal women is ERα/ERβ ratio dependent.	ESR1 ESR2	2.64e-06	2	57	2	23499841
Pubmed	The ERalpha/ERbeta ratio determines oxidative stress in breast cancer cell lines in response to 17beta-estradiol.	ESR1 ESR2	2.64e-06	2	57	2	22615145
Pubmed	Novel effects of estradiol and estrogen receptor alpha and beta on cognitive function.	ESR1 ESR2	2.64e-06	2	57	2	11074057
Interaction	RGPD4 interactions	RGPD4 RGPD2 CFTR RGPD3	3.77e-07	22	56	4	int:RGPD4
Interaction	RGPD2 interactions	RGPD4 RGPD2 CFTR RGPD3	8.95e-07	27	56	4	int:RGPD2
Interaction	RGPD3 interactions	RGPD4 RGPD2 ESR1 RGPD3	8.72e-06	47	56	4	int:RGPD3
Interaction	RGPD1 interactions	RGPD4 RGPD2 CFTR RGPD3	1.03e-05	49	56	4	int:RGPD1
Interaction	PRKAR2A interactions	ESR1 ESR2 CFTR PSMD2 PRKCI RYR2	3.01e-05	217	56	6	int:PRKAR2A
Interaction	NTPCR interactions	ESR1 ESR2 CFTR WDFY1 EPHA7	3.77e-05	136	56	5	int:NTPCR
Interaction	PTCD1 interactions	ESR1 ESR2 CFTR ZBTB47 FASTKD2	4.63e-05	142	56	5	int:PTCD1
Interaction	DAAM1 interactions	ATP6V1H ESR1 ESR2 CFTR	4.78e-05	72	56	4	int:DAAM1
Interaction	RGPD8 interactions	RGPD4 RGPD2 RGPD3 PSMD2	5.32e-05	74	56	4	int:RGPD8
Interaction	RANBP2 interactions	RGPD4 RGPD2 ESR1 ESR2 CFTR RGPD3 DHX9	6.09e-05	361	56	7	int:RANBP2
Interaction	MSL3B interactions	ESR1 ESR2	7.54e-05	5	56	2	int:MSL3B
Interaction	OGDH interactions	USP13 ESR1 ESR2 ADAM7 FASTKD2 DHX9	7.56e-05	256	56	6	int:OGDH
Interaction	ERBIN interactions	ESR1 ESR2 CFTR PRKCI EPHA7 ZNF563	9.14e-05	265	56	6	int:ERBIN
Interaction	GNAI2 interactions	IARS2 ESR1 ESR2 PAK5 CFTR CXCR2	1.17e-04	277	56	6	int:GNAI2
Interaction	ZNF652 interactions	SALL3 ESR1 ESR2	1.25e-04	35	56	3	int:ZNF652
Interaction	RGPD5 interactions	RGPD4 RGPD2 RGPD3 PSMD2	1.47e-04	96	56	4	int:RGPD5
Interaction	RFTN1 interactions	RFTN1 ESR1 ESR2	1.48e-04	37	56	3	int:RFTN1
Interaction	LAMTOR1 interactions	ARFGEF3 RFTN1 IARS2 PIK3C2B CNIH4 ESR1 ESR2 CEMIP2 EPHA7	1.55e-04	722	56	9	int:LAMTOR1
Interaction	SORCS1 interactions	CFTR RYR2	1.58e-04	7	56	2	int:SORCS1
GeneFamily	Zinc fingers C2H2-type\|ZF class homeoboxes and pseudogenes	ZBTB34 SALL3 ZNF556 ZNF366 ZBTB47 ZNF799 RREB1 ZNF441 ZFPM2 ZNF563	5.35e-06	718	43	10	28
GeneFamily	Tetratricopeptide repeat domain containing\|Bardet-Biedl syndrome associated\|BBSome	RGPD4 RGPD2 RGPD3 TTC13	1.58e-04	115	43	4	769
GeneFamily	DEAH-box helicases	DHX36 DHX9	6.49e-04	16	43	2	500
GeneFamily	Nuclear hormone receptors	ESR1 ESR2	6.05e-03	49	43	2	71
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARFGEF3 STAB2 CFTR CNTNAP4 RYR2 EPHA7	1.32e-07	184	57	6	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARFGEF3 STAB2 CFTR CNTNAP4 RYR2 EPHA7	1.32e-07	184	57	6	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARFGEF3 STAB2 CFTR CNTNAP4 RYR2 EPHA7	1.32e-07	184	57	6	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	3'-Adult-SmallIntestine-Epithelial-mature_enterocytic-Paneth\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TBC1D16 ZNF556 ESR2 TM6SF2 ZNF563	2.05e-06	162	57	5	768a566e76923323c1f197f60bab472a8784490b
ToppCell	human_hepatoblastoma-Tumor_cells-T6\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	ESR1 ESR2 ZFPM2 RYR2 CEMIP2	3.34e-06	179	57	5	14fc8ccb6b215063d747643f47d780d2b237eb67
ToppCell	droplet-Lung-LUNG-1m-Epithelial-Club_Cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARFGEF3 FAM178B CFTR PIGW SHC4	4.02e-06	186	57	5	e52cf44989c57c433bf82e9fa13b4643e88f3577
ToppCell	droplet-Lung-LUNG-1m-Epithelial-club_cell_of_bronchiole\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARFGEF3 FAM178B CFTR PIGW SHC4	4.02e-06	186	57	5	4c0b59d845b79323e7a3287e7c4d249f5f322556
ToppCell	COVID-19-kidney-Technical/muscle_(PCT)\|kidney / Disease (COVID-19 only), tissue and cell type	FAM178B DNAH2 CNTNAP4 RYR2	3.68e-05	146	57	4	c55f1bdb6ac43b4118cb27ea7c879527e1afcbab
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic-precursor_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PAK5 CFTR CNTNAP4 RYR2	5.25e-05	160	57	4	c381ec6be8cf887861cc18f831a20db42f953fe1
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic-pre_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PAK5 CFTR CNTNAP4 RYR2	5.25e-05	160	57	4	25c8f3d2a6d14ff0ca0b965fce89d3ff22f40585
ToppCell	(7)_MNP-(7)_DC_activated\|(7)_MNP / Spleen cell shreds - cell class (v1) and cell subclass (v1)	RFTN1 NRXN2 ZNF366 ZNF563	6.65e-05	170	57	4	4ab495b38a071fa8207331df2ce0d78a2dcd034e
ToppCell	COVID-19-kidney-PEC\|kidney / Disease (COVID-19 only), tissue and cell type	RFTN1 BICC1 ZFPM2 EPHA7	6.96e-05	172	57	4	36a96714a0eb6ac438648135336c9791881ddadb
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex-lymphatic_endothelial_cell_of_renal_cortex\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	STAB2 PIGW SHC4 ZFPM2	7.44e-05	175	57	4	9a96a946db731ba24c9be34bedebf1f4a1372b9e
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-lymphatic_endothelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	STAB2 PIGW SHC4 ZFPM2	7.44e-05	175	57	4	54c1f080195ad8392a095e83b56a4b54073d4c0d
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	STAB2 PIGW SHC4 ZFPM2	7.44e-05	175	57	4	2b51406a2c2daa13ab4ed283ede038cd11d9e641
ToppCell	metastatic_Brain-Endothelial_cells-Lymphatic_ECs\|metastatic_Brain / Location, Cell class and cell subclass	TBC1D16 STAB2 TM9SF1 BICC1	8.12e-05	179	57	4	56fe381ffbaba3a4f2f587a3e367b0d11fbd4a2a
ToppCell	COVID-19-Heart-EC_2\|COVID-19 / Disease (COVID-19 only), tissue and cell type	RFTN1 PIK3C2B ZNF366 ESR2	8.12e-05	179	57	4	2a53d94f6c30bf887dfe88f1693ea057218c852d
ToppCell	E16.5-samps-Endothelial-Immature_fetal_endothelial-Proliferative_Endothelial\|E16.5-samps / Age Group, Lineage, Cell class and subclass	RFTN1 STAB2 PIK3C2B CEMIP2	8.12e-05	179	57	4	d24513a404c9b1d37dd47aa1cdb5713b64b88f89
ToppCell	droplet-Liver-Npc-21m-Endothelial-endothelial_cell_of_hepatic_sinusoid\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	STAB2 NRXN2 ZFPM2 CEMIP2	8.66e-05	182	57	4	b1ec2015aad1181eac1bbf8d48ad6f2f7ed24a01
ToppCell	Control-Stromal_mesenchymal-Lung_smooth_muscle-MatrixFB_->_Myofibroblast\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	BICC1 ZFPM2 RYR2 EPHA7	8.84e-05	183	57	4	7eae9b3b4d1c9b135fa7cff348393d4adec474b4
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m-Epithelial-neuroepithelial_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DNAH2 RREB1 ZFPM2 CEMIP2	9.22e-05	185	57	4	05bc89a566b0db90ae06506e067190a4739a0974
ToppCell	Adult-Epithelial-club_cell-D231\|Adult / Lineage, Cell type, age group and donor	ARFGEF3 CFTR SHC4 EPHA7	9.61e-05	187	57	4	ee59d7d3de5879738ff0b9c3ea5e4847fb48cb86
ToppCell	COPD-Epithelial-ATII\|Epithelial / Disease state, Lineage and Cell class	RFTN1 USP13 CFTR CEMIP2	9.61e-05	187	57	4	030af361f8bdcd0aff4ec1922702833325cf74d8
ToppCell	facs-Lung-EPCAM-3m-Epithelial-type_II_pneumocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARFGEF3 ADAM7 CFTR EPHA7	9.81e-05	188	57	4	3dd571bd8e7358b4346dea71f6bf9602dabf583c
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RFTN1 MGAT5B ZFPM2 RYR2	9.81e-05	188	57	4	50c1b1d690f0e9443082f2adf4f1b8e9ce4cd337
ToppCell	facs-Lung-EPCAM-3m-Epithelial-Alveolar_Epithelial_Type_2\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARFGEF3 ADAM7 CFTR EPHA7	9.81e-05	188	57	4	b1049003ca79c340bb8c78da66bdc0956e1aebc2
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	TBC1D16 PRKCI BICC1 EPHA7	1.00e-04	189	57	4	1ecf9911ff82e0ca0f0c101b735d3b1f3b339d57
ToppCell	Adult-Epithelial-club_cell\|Adult / Lineage, Cell type, age group and donor	ARFGEF3 CFTR SHC4 EPHA7	1.02e-04	190	57	4	756bff697d30aec56c0ebfca94295f084a15bf37
ToppCell	droplet-Lung-immune-endo-depleted-3m-Epithelial-type_II_pneumocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARFGEF3 FAM178B CFTR EPHA7	1.02e-04	190	57	4	aaf5f1c1ff7b1454f4e5dacfeb48e1c3627e3372
ToppCell	droplet-Lung-immune-endo-depleted-3m-Epithelial-Alveolar_Epithelial_Type_2\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARFGEF3 FAM178B CFTR EPHA7	1.02e-04	190	57	4	a20123d5c6cb8c2f0dfd99bbfdb571a73c36234d
ToppCell	droplet-Lung-30m-Endothelial-lymphatic_endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell\|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	STAB2 NRXN2 FAM178B ZFPM2	1.04e-04	191	57	4	51cff0594ac7ad8c065c8ea2301f8c149bd062b4
ToppCell	droplet-Lung-18m-Epithelial-alveolar_epithelial\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ARFGEF3 FAM178B CFTR EPHA7	1.04e-04	191	57	4	caed913e7ede9f8ae3af273d1ecf375de6c5e813
ToppCell	droplet-Lung-30m-Endothelial-lymphatic_endothelial-lymphatic_endothelial_cell\|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	STAB2 NRXN2 FAM178B ZFPM2	1.04e-04	191	57	4	a55b6f0a7ec1a8852ffca593cfdccd7edea09b7b
ToppCell	droplet-Lung-30m-Endothelial-lymphatic_endothelial\|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	STAB2 NRXN2 FAM178B ZFPM2	1.04e-04	191	57	4	38681a1b182d6af5cce85db5431b6eba4b20ad96
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	RFTN1 ESR1 ESR2 ZFPM2	1.11e-04	194	57	4	81713e0409e8be695ba5dfdc67a997b33435dd9e
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	RFTN1 ESR1 ESR2 ZFPM2	1.11e-04	194	57	4	627cffe2d448e74fc5df92e74e5b922a73304137
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_2_cell-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	NRXN2 BICC1 ZFPM2 RYR2	1.15e-04	196	57	4	525d6c8a277364e624e7cc586275f8a891436b57
ToppCell	facs-Liver-Liver_non-hepato/SCs-18m-Endothelial\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	STAB2 NRXN2 PIK3C2B CEMIP2	1.17e-04	197	57	4	d584d0334ea97e3fa8c4cd869f5eeea2c7a1ed04
ToppCell	Bronchus_Control_(B.)-Epithelial-TX-AT1\|Bronchus_Control_(B.) / Sample group, Lineage and Cell type	STAB2 ZNF556 CFTR ZBTB47	1.17e-04	197	57	4	f7ef62d78336812573148f8bfce401877ec4e29c
ToppCell	facs-Liver-Liver_non-hepato/SCs-18m-Endothelial-endothelial_cell_of_hepatic_sinusoid\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	STAB2 NRXN2 PIK3C2B CEMIP2	1.17e-04	197	57	4	412091994196a06c2779b4c2cfed84be889a5f8d
ToppCell	Parenchymal-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	FAM178B BICC1 RYR2 EPHA7	1.20e-04	198	57	4	d1827e3707b929e3a3562989a0c11537d344e164
ToppCell	Neuron-Postmitotic-Excitatory_Neuron_-Parietal_and_Temporal-6\|World / Primary Cells by Cluster	ARFGEF3 PAK5 RYR2 EPHA7	1.22e-04	199	57	4	1b1bccf4293f11048709d15a3c892c0edf3da3d2
ToppCell	Neuron-Postmitotic-Excitatory_Neuron_-Parietal_and_Temporal\|World / Primary Cells by Cluster	ARFGEF3 PAK5 RYR2 EPHA7	1.22e-04	199	57	4	4bee94c116c0da5eba951cb4cea7cc9dcdd6e30f
Drug	4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol	ESR1 ESR2 RYR2	1.24e-06	9	57	3	ctd:C556295
Drug	Tx F	ESR1 ESR2 CXCR2	5.31e-06	14	57	3	CID006852176
Drug	5-octylphenol	ESR1 ESR2	6.16e-06	2	57	2	ctd:C113977
Drug	Pyrazolo[1,5-a]pyrimidine, 12d	ESR1 ESR2	6.16e-06	2	57	2	CID016103245
Drug	Pyrazolo[1,5-a]pyrimidine, 12c	ESR1 ESR2	6.16e-06	2	57	2	CID016103238
Drug	tetradifon	ESR1 ESR2	6.16e-06	2	57	2	ctd:C005807
Drug	SureCN3587271	ESR1 ESR2	6.16e-06	2	57	2	CID011208678
Drug	CNP-amino	ESR1 ESR2	6.16e-06	2	57	2	CID000033473
Drug	ERB 041	ESR1 ESR2	6.16e-06	2	57	2	ctd:C478102
Drug	etocrylene	ESR1 ESR2	6.16e-06	2	57	2	CID000243274
Drug	(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL	ESR1 ESR2	6.16e-06	2	57	2	DB07933
Drug	4-(4-hydroxyphenyl)-6-methyl-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol	ESR1 ESR2	6.16e-06	2	57	2	CID010125512
Drug	Raloxifene	ESR1 ESR2	6.16e-06	2	57	2	DB00481
Drug	Brn 0187733	ESR1 ESR2	6.16e-06	2	57	2	CID000160446
Drug	2-phenylbenzofuran	ESR1 ESR2	6.16e-06	2	57	2	CID003517936
Drug	PHTPP	ESR1 ESR2	6.16e-06	2	57	2	CID011201035
Drug	butolame	ESR1 ESR2	6.16e-06	2	57	2	CID000197608
Drug	LY 326315	ESR1 ESR2	6.16e-06	2	57	2	CID009803972
Drug	JK 1624F2-1	ESR1 ESR2	6.16e-06	2	57	2	ctd:C113642
Drug	steroid C	ESR1 ESR2	6.16e-06	2	57	2	CID000454473
Drug	2z4b	ESR1 ESR2	6.16e-06	2	57	2	CID011197931
Drug	octocrylene	ESR1 ESR2	6.16e-06	2	57	2	ctd:C088673
Drug	O-desmethylangolensin	ESR1 ESR2	6.16e-06	2	57	2	ctd:C050052
Drug	dehydroestrone	ESR1 ESR2	6.16e-06	2	57	2	CID000102225
Drug	(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL	ESR1 ESR2	6.16e-06	2	57	2	DB07638
Drug	CHEMBL397775	ESR1 ESR2	6.16e-06	2	57	2	CID010214678
Drug	prolame	ESR1 ESR2	6.16e-06	2	57	2	CID000127441
Drug	benzohydrol	ESR1 ESR2	6.16e-06	2	57	2	ctd:C020225
Drug	parthenocissin A	ESR1 ESR2	6.16e-06	2	57	2	ctd:C549189
Drug	Cyclohexanone, 3b	ESR1 ESR2	6.16e-06	2	57	2	CID011370317
Drug	CHEBI:428946	ESR1 ESR2	6.16e-06	2	57	2	CID011688293
Drug	F ppt	ESR1 ESR2	6.16e-06	2	57	2	CID003035869
Drug	CHEMBL234633	ESR1 ESR2	6.16e-06	2	57	2	CID010192968
Drug	SureCN14514707	ESR1 ESR2	6.16e-06	2	57	2	CID010192967
Drug	SureCN3118249	ESR1 ESR2	6.16e-06	2	57	2	CID011519653
Drug	SureCN4017709	ESR1 ESR2	6.16e-06	2	57	2	CID011256602
Drug	CHEBI:428959	ESR1 ESR2	6.16e-06	2	57	2	CID011638242
Drug	DNC005795	ESR1 ESR2	6.16e-06	2	57	2	CID011638264
Drug	tetrahydrodaidzein	ESR1 ESR2	6.16e-06	2	57	2	ctd:C433164
Drug	tri-(2-ethylhexyl)trimellitate	ESR1 ESR2	6.16e-06	2	57	2	ctd:C036101
Drug	2-chloro-4-phenylphenol	ESR1 ESR2	6.16e-06	2	57	2	ctd:C012257
Drug	2,2,4-trimethyl-1,3-pentanediol diisobutyrate	ESR1 ESR2	6.16e-06	2	57	2	ctd:C001508
Drug	2-(3-chloro-4-hydroxyphenyl)-2-(4-hydroxyphenyl)propane	ESR1 ESR2	6.16e-06	2	57	2	ctd:C497826
Drug	2,2-bis(3-chloro-4-hydroxyphenyl)propane	ESR1 ESR2	6.16e-06	2	57	2	ctd:C497827
Drug	1-ethyl-2-(4-hydroxyphenyl)-3H-inden-5-ol	ESR1 ESR2	6.16e-06	2	57	2	CID011615788
Drug	SureCN3593776	ESR1 ESR2	6.16e-06	2	57	2	CID009948127
Drug	SureCN14047367	ESR1 ESR2	6.16e-06	2	57	2	CID010171723
Drug	(4R)-6-(ethoxymethyl)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol	ESR1 ESR2	6.16e-06	2	57	2	CID011175195
Drug	Y134 compound	ESR1 ESR2	6.16e-06	2	57	2	ctd:C518540
Drug	TS 108	ESR1 ESR2	6.16e-06	2	57	2	ctd:C482068
Drug	(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL	ESR1 ESR2	6.16e-06	2	57	2	DB08020
Drug	ethyl cinnamate	ESR1 ESR2	6.16e-06	2	57	2	ctd:C451418
Drug	(4R)-4-(4-hydroxyphenyl)-6-methylol-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol	ESR1 ESR2	6.16e-06	2	57	2	CID011174414
Drug	Estriol	ESR1 ESR2	6.16e-06	2	57	2	DB04573
Drug	Estropipate	ESR1 ESR2	6.16e-06	2	57	2	DB04574
Drug	CHEBI:428952	ESR1 ESR2	6.16e-06	2	57	2	CID011674420
Drug	phytoene	ESR1 ESR2	6.16e-06	2	57	2	ctd:C100185
Drug	6-(4-hydroxyphenyl)-6,6a,7,8,9,10,11,11a-octahydrocyclohepta[c]chromen-2-ol	ESR1 ESR2	6.16e-06	2	57	2	CID010215026
Drug	4-(2-chloro-4-(2-piperidin-1-ylethoxy)phenyl)-5-(2,6-dichloro-4-hydroxyphenyl)-2-imidazoline	ESR1 ESR2	6.16e-06	2	57	2	ctd:C496952
Drug	CHEMBL48352	ESR1 ESR2	6.16e-06	2	57	2	CID011522286
Drug	bromophos	ESR1 ESR2	6.16e-06	2	57	2	ctd:C100092
Drug	indenestrol	ESR1 ESR2	6.16e-06	2	57	2	ctd:C047437
Drug	SureCN14514705	ESR1 ESR2	6.16e-06	2	57	2	CID010125414
Drug	[5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE	ESR1 ESR2	6.16e-06	2	57	2	DB06927
Drug	3,4-dihydroxybenzaldoxime	ESR1 ESR2	6.16e-06	2	57	2	ctd:C053286
Drug	Tamoxifen	ESR1 ESR2	6.16e-06	2	57	2	DB00675
Drug	SureCN14514737	ESR1 ESR2	6.16e-06	2	57	2	CID010149292
Drug	di-(5-methylhexyl)phthalate	ESR1 ESR2	6.16e-06	2	57	2	ctd:C042791
Drug	phytofluene	ESR1 ESR2	6.16e-06	2	57	2	ctd:C003140
Drug	LY2066948	ESR1 ESR2	6.16e-06	2	57	2	CID005327043
Drug	1x7e	ESR1 ESR2	6.16e-06	2	57	2	CID000656953
Drug	SERBA-2	ESR1 ESR2	6.16e-06	2	57	2	CID009925763
Drug	SureCN1360427	ESR1 ESR2	6.16e-06	2	57	2	CID011720174
Drug	salicylaldoxime	ESR1 ESR2	6.16e-06	2	57	2	ctd:C005704
Drug	16 alpha-iodoestradiol	ESR1 ESR2	6.16e-06	2	57	2	ctd:C024871
Drug	2,3-bis(4-hydroxyphenyl)-propionitrile	ESR1 ESR2 RYR2	6.63e-06	15	57	3	ctd:C486182
Drug	Bicarbonates	ESR1 ESR2 CFTR	8.14e-06	16	57	3	ctd:D001639
Drug	polyethylenimine	ATP6V1H ESR1 ESR2 CFTR RYR2	1.72e-05	128	57	5	CID000009033
Drug	benzophenone-6	ESR1 ESR2	1.84e-05	3	57	2	CID000008570
Drug	dichlofenthion	ESR1 ESR2	1.84e-05	3	57	2	CID000007328
Drug	2-(((3,5-dichlorophenyl)carbamoyl)oxy)-2-methyl-3-butenoic acid	ESR1 ESR2	1.84e-05	3	57	2	ctd:C101851
Drug	Nafoxidine	ESR1 ESR2	1.84e-05	3	57	2	ctd:D009256
Drug	LY2066948	ESR1 ESR2	1.84e-05	3	57	2	ctd:C504960
Drug	CHF 4056	ESR1 ESR2	1.84e-05	3	57	2	ctd:C450419
Drug	Diethylstilbestrol	ESR1 ESR2	1.84e-05	3	57	2	DB00255
Drug	AC1LGHHD	ESR1 ESR2	1.84e-05	3	57	2	CID000821427
Drug	cyanophenphos	ESR1 ESR2	1.84e-05	3	57	2	ctd:C002488
Drug	p-tert-amylphenol	ESR1 ESR2	1.84e-05	3	57	2	ctd:C019566
Drug	1-(4-nitro-2-(trifluoromethyl)phenyl)-4-(3-(trifluoromethyl)phenyl)piperazine	ESR1 ESR2	1.84e-05	3	57	2	ctd:C562246
Drug	Chromans	ESR1 ESR2	1.84e-05	3	57	2	ctd:D002839
Drug	2,4,6-trichlorophenyl-4'-aminophenyl ether	ESR1 ESR2	1.84e-05	3	57	2	ctd:C067259
Drug	7alpha-methyl-17alpha-ethynylestradiol	ESR1 ESR2	1.84e-05	3	57	2	ctd:C475050
Drug	4-hydroxybenzophenone	ESR1 ESR2	1.84e-05	3	57	2	ctd:C024292
Drug	bromophos-ethyl	ESR1 ESR2	1.84e-05	3	57	2	CID000020965
Drug	dihydrobiochanin A	ESR1 ESR2	1.84e-05	3	57	2	CID000439784
Drug	rhapontigenin	ESR1 ESR2	1.84e-05	3	57	2	ctd:C431126
Drug	Estradiol	ESR1 ESR2	1.84e-05	3	57	2	DB00783
Drug	Norgestrel	ESR1 ESR2	1.84e-05	3	57	2	ctd:D009644
Drug	bicyclo(3.3.1)nonane	ESR1 ESR2	1.84e-05	3	57	2	CID000136101
Drug	cedrol	ESR1 ESR2	1.84e-05	3	57	2	ctd:C078669
Disease	prostate carcinoma in situ (implicated_via_orthology)	ESR1 ESR2	3.29e-06	2	54	2	DOID:8634 (implicated_via_orthology)
Disease	peritonitis (implicated_via_orthology)	ESR1 ESR2	9.85e-06	3	54	2	DOID:8283 (implicated_via_orthology)
Disease	venous thromboembolism, von Willebrand factor measurement	STAB2 ZNF366 ZFPM2	6.32e-05	42	54	3	EFO_0004286, EFO_0004629
Disease	synaptotagmin-11 measurement	RREB1 ZFPM2	1.17e-04	9	54	2	EFO_0802108
Disease	Metastatic melanoma	PAK5 PRKCI EPHA7	1.35e-04	54	54	3	C0278883
Disease	Prostatic Intraepithelial Neoplasias	ESR1 ESR2	1.79e-04	11	54	2	C0282612
Disease	trypsin-3 measurement	ZNF799 RREB1	1.79e-04	11	54	2	EFO_0020791
Disease	gout	NRXN2 CNIH4 CFTR RREB1	4.61e-04	196	54	4	EFO_0004274
Disease	Uterine leiomyoma, estrogen-receptor positive breast cancer	ESR1 ZFPM2	4.94e-04	18	54	2	EFO_1000649, HP_0000131
Disease	in situ carcinoma (is_marker_for)	ESR1 ESR2	6.75e-04	21	54	2	DOID:8719 (is_marker_for)
Disease	osteoporosis (biomarker_via_orthology)	ESR1 ESR2	7.42e-04	22	54	2	DOID:11476 (biomarker_via_orthology)
Disease	neutrophil count, basophil count	ZNF366 PSMD2 RREB1 CXCR2	7.59e-04	224	54	4	EFO_0004833, EFO_0005090
Disease	cancer	PIK3C2B ESR1 PRKCI RREB1 TRPV5	8.18e-04	400	54	5	MONDO_0004992
Disease	Cerebral Astrocytoma	ESR1 ESR2	9.60e-04	25	54	2	C0750935
Disease	Intracranial Astrocytoma	ESR1 ESR2	9.60e-04	25	54	2	C0750936
Disease	Pilocytic Astrocytoma	ESR1 ESR2	9.60e-04	25	54	2	C0334583
Disease	Astrocytoma	ESR1 ESR2	9.60e-04	25	54	2	C0004114
Disease	Juvenile Pilocytic Astrocytoma	ESR1 ESR2	9.60e-04	25	54	2	C0280783
Disease	Diffuse Astrocytoma	ESR1 ESR2	9.60e-04	25	54	2	C0280785
Disease	Grade I Astrocytoma	ESR1 ESR2	9.60e-04	25	54	2	C1704230
Disease	Subependymal Giant Cell Astrocytoma	ESR1 ESR2	9.60e-04	25	54	2	C0205768
Disease	Mixed oligoastrocytoma	ESR1 ESR2	9.60e-04	25	54	2	C0547065
Disease	Childhood Cerebral Astrocytoma	ESR1 ESR2	9.60e-04	25	54	2	C0338070
Disease	calcium measurement	FAM178B ESR2 DNAH2 RREB1 TM6SF2 ZFPM2	9.85e-04	628	54	6	EFO_0004838
Disease	Gemistocytic astrocytoma	ESR1 ESR2	1.04e-03	26	54	2	C0334581
Disease	Protoplasmic astrocytoma	ESR1 ESR2	1.04e-03	26	54	2	C0334580
Disease	Fibrillary Astrocytoma	ESR1 ESR2	1.04e-03	26	54	2	C0334582
Disease	Anaplastic astrocytoma	ESR1 ESR2	1.12e-03	27	54	2	C0334579
Disease	factor VIII measurement, von Willebrand factor measurement	STAB2 ZNF366	1.12e-03	27	54	2	EFO_0004629, EFO_0004630
Disease	Subfertility, Female	ESR1 ESR2	1.21e-03	28	54	2	C0341869
Disease	Sterility, Postpartum	ESR1 ESR2	1.21e-03	28	54	2	C0038279
Disease	osteoarthritis (is_implicated_in)	ESR1 ESR2	1.21e-03	28	54	2	DOID:8398 (is_implicated_in)
Disease	Female sterility	ESR1 ESR2	1.21e-03	28	54	2	C0917730
Disease	Female infertility	ESR1 ESR2	1.21e-03	28	54	2	C0021361
Disease	osteoporosis (is_implicated_in)	ESR1 ESR2	1.48e-03	31	54	2	DOID:11476 (is_implicated_in)
Disease	unipolar depression	TBC1D16 ZBTB34 CNIH4 ESR1 ESR2 SHC4 ZFPM2 EPHA7	1.49e-03	1206	54	8	EFO_0003761
Disease	melanoma (is_marker_for)	ESR1 ESR2	1.67e-03	33	54	2	DOID:1909 (is_marker_for)
Disease	factor VIII measurement, venous thromboembolism	STAB2 ZFPM2	1.78e-03	34	54	2	EFO_0004286, EFO_0004630
Disease	bitter alcoholic beverage consumption measurement	MLF2 NRXN2 DNAH2	1.88e-03	133	54	3	EFO_0010092
Disease	soluble triggering receptor expressed on myeloid cells 2 measurement	TBC1D16 IARS2 CFTR EPHA7	2.12e-03	296	54	4	EFO_0010151
Disease	hematocrit	ESR2 DNAH2 TTC13 RREB1 TM6SF2 BICC1 ZFPM2	2.36e-03	1011	54	7	EFO_0004348
Disease	Diaphragmatic Hernia	CFTR ZFPM2	2.58e-03	41	54	2	C0019284
Disease	multiple sclerosis symptom measurement	STAB2 EPHA7	3.23e-03	46	54	2	EFO_0803536
Disease	systemic lupus erythematosus (is_marker_for)	ESR2 CXCR2	3.37e-03	47	54	2	DOID:9074 (is_marker_for)
Disease	Male sterility	ESR1 CFTR	3.51e-03	48	54	2	C0917731

Protein segments in the cluster

Peptide	Gene	Start	Entry
AIFGLHHIGMQMRIA	CFTR	141	P13569
NRMAHQLGHNLGMQH	ADAM7	331	Q9H2U9
KNMADGQLHHIMINR	CNTNAP4	1096	Q9C0A0
IAAQHHLFMMGRNGS	BICC1	291	Q9H694
HLFMMGRNGSNIKHI	BICC1	296	Q9H694
MNSGAMRIHSKGHFQ	DBF4	1	Q9UBU7
RRMQQMAGHLGAFHP	CELF6	221	Q96J87
HLKSFSMANGLNARM	RAB40B	221	Q12829
HMSDHFRKGGMLVNA	RFTN1	321	Q14699
RGSHAAKQNGHVMKM	PAK5	161	Q9P286
NGGDLMFHMQRQRKL	PRKCI	336	P41743
RHASNKGMEHLLNMK	ESR2	466	Q92731
RALEMHLNSHSGVKM	ZFPM2	311	Q8WW38
TDYHGLQQMKRHMGL	MGAT5B	366	Q3V5L5
LSHIRHMSNKGMEHL	ESR1	511	P03372
RTLFKAHMGQKHRAM	CXCR2	236	P25025
AHMGQKHRAMRVIFA	CXCR2	241	P25025
GQMAGAHMRLEFHNI	NRXN2	846	Q9P2S2
IQTMRAQMLHLHGTG	EPHA7	981	Q15375
RHNDNIMLKTTGHMF	PIK3C2B	1196	O00750
YMHAGSLLLKMGQHG	RGPD3	291	A6NKT7
QLLMHGTKYSMNHEG	IGSF22	456	Q8N9C0
LQMLHNMKGQFAEHL	DHX36	791	Q9H2U1
RPQHLMDQGQMRHSF	ARFGEF3	2066	Q5TH69
LKHMGQQQMGRYPVH	CEMIP2	536	Q9UHN6
EHMGMAQRFHALSLG	DNAH2	3856	Q9P225
AVVLQQHIRMHMGGQ	SALL3	751	Q9BXA9
GFLHVFAHMQMKLSQ	RYR2	3946	Q92736
MQKHLEMNPHFGSHR	DHX9	666	Q08211
AIHRQHMSRMLSGGF	MLF2	21	Q15773
YMHAGSLLLKMGQHG	RGPD4	291	Q7Z3J3
LGGKQLVMNHMHHED	ATP6V1H	431	Q9UI12
MHAGSLLLKMGQHGN	RGPD2	291	P0DJD1
QKQMAFMLGRHGVFL	PSMD2	291	Q13200
LHFTGQMSHGLQMAG	FAM178B	21	Q8IXR5
AMKMRHLNAMGFHVI	FASTKD2	656	Q9NYY8
ANRFHMMNGSKIHFV	IARS2	136	Q9NSE4
HTLQKHMMFIQRFGV	TBC1D26	151	Q86UD7
HMAGVQTGLYMHKNR	PIGW	316	Q7Z7B1
IHNRGQLKSHMKEAM	CNIH4	101	Q9P003
RQDRHFLQHLLGMGM	SHC4	176	Q6S5L8
VQTLQLRGMMLYHHG	TTC13	351	Q8NBP0
HLKSFQRHMIMHTGD	ZNF441	486	Q8N8Z8
ELRKLMMLHGGQYHV	REV1	66	Q9UBZ9
GQSFTTNGNMHRHMK	RREB1	131	Q92766
MLLHFGNLAMHMNGE	TBC1D16	666	Q8TBP0
QKSFRVHMIMHAGGR	ZNF556	271	Q9HAH1
REGHLQQGNMHKNMR	nan	296	A8MX80
KAFHHLGSFQRHMVM	ZNF799	316	Q96GE5
KNDLHNGMHRETMLG	STAB2	1211	Q8WWQ8
LRSHMSIHIGHKQFM	ZBTB47	591	Q9UFB7
FRRHMVMHTGDGPNK	ZNF563	436	Q8TA94
GKEFNRMHNLMGHMH	ZNF366	511	Q8N895
HTLQKHMMFIQRFGV	TBC1D28	151	Q2M2D7
IGQAQFSHMGASMHL	TM6SF2	306	Q9BZW4
KHNISHMSMDIARGL	WDFY1	366	Q8IWB7
FGIDMLHMHGTENGL	USP13	291	Q92995
VMALLGMFNVHRHGA	TM9SF1	326	O15321
GNTVMFQHLMQKRRH	TRPV5	251	Q9NQA5
FNQKGSLDRHMRLHM	ZBTB34	381	Q8NCN2